Everyone deserves high-quality, affordable breast cancer care. But getting it isn't always easy. Explore resources that can help: bit.ly/4kxzaz4 #breastcancer #breastcancersurvivor #tnbc #metavivor

UTIs are common, uncomfortable, and sometimes hard to avoid. And while women are more likely to get them than men, menopause and certain breast cancer treatments can increase their risk even further. Whether you've had one UTI or several, here are nine everyday habits to try to help lower your risk. bit.ly/44wK2Ec #breastcancer #breastcancerwarrior #menopause #womenshealth

It can be easy to be tricked by the breast cancer misinformation spreading online. From claims that sugar causes cancer to wearing a bra, these myths just won't seem to die. ⚰️ Read all 12 myths that have us spooked: bit.ly/3YfmuQD 👻 #breastcancer #breastcancerawareness #womenshealth #halloween

Thanks to the incredible generosity of our community, we’ve reached our initial $50,000 fundraising goal! And now our Board of Directors is offering an additional $10,000, bringing the total to $60,000! 🙌 Make twice the difference withe a gift today: bit.ly/4emRPtB 💝 $10 becomes $20 💝 $25 becomes $50 💝 $75 becomes $150 💝 $150 becomes $300 #charity #breastcancer #breastcancersupport #breastcancerawareness

New results from the HEALER trial presented at #ESMO26 suggest anbenitamab plus HB1801 may help people with HER2-positive metastatic breast cancer live longer without the cancer growing. 🔗 bit.ly/4ewhPCh #BreastCancer #BreastCancerResearch #InsightsbyESMO #ClinicalTrials #BreastCancerTreatment #BreastCancerAwareness

New results from the HORIZON-Breast06 trial presented at #ESMO26 suggest trastuzumab rezetecan may help people with HER2-low metastatic breast cancer live longer without the cancer growing. bit.ly/4ewhPCh #BreastCancer #BreastCancerResearch #InsightsbyESMO #ClinicalTrials #BreastCancerTreatment

New results from the NATALEE trial presented at #ESMO26 suggest that adding Kisqali to an aromatase inhibitor may help people with early-stage HR+, HER2-negative breast cancer live longer. Overall survival rates (how long people live, whether or not the cancer comes back) were: 📊 At 5 years: 94% vs. 93% 📊 At 6 years: 92% vs. 90% Both results favored the Kisqali combination over an aromatase inhibitor alone. 🔗Read more: bit.ly/4ewhPCh #BreastCancer #BreastCancerResearch #InsightsbyESMO #BreastCancerTreatment

Read more breast cancer research results coming out of #ESMO26 here: bit.ly/4ewhPCh #Breastcancer #Breastcancerresearch #TNBC

New findings from the FOURLIGHT-1 trial presented at #ESMO26 suggest atirmociclib plus Faslodex may help people with HR+, HER2-negative metastatic breast cancer live longer without the cancer growing. 🔗 Read more: bit.ly/4ewhPCh #BreastCancer #BreastCancerResearch #ESMO26 #InsightsbyESMO #ClinicalTrials #Metavivor

New postMONARCH findings presented at #ESMO26 suggest Verzenio plus Faslodex may improve survival in advanced hormone receptor-positive breast cancer after progression on a CDK4/6 inhibitor. Median overall survival was 32 vs. 24.6 months, though the difference wasn't statistically significant. The combination also improved progression-free survival. 🔗 Read more: bit.ly/4ewhPCh #BreastCancer #BreastCancerResearch #InsightsbyESMO #ClinicalTrials #BreastCancerTreatment

Karim Fizazi in the #ESMO26 opening session recapped the year in oncology with a big picture overview beyond drug data. 📉 GLP-1 receptor agonists tied to lower cancer incidence in diabetic and obese patients 💬 AI agents near expert level on selected oncology decisions, Ferber Nature 2026, with human oversight still required 📋 MFN pricing may shift global launch strategies and access worldwide 👥 Estimated 100 million healthcare worker shortfall by 2050 Staffing and AI validation are the two that are already touching trial operations. #ESMO26 #AIinMedicine #GUonc

An experimental breast cancer treatment may help people with hormone receptor-positive, HER2-negative metastatic breast cancer live longer without the cancer growing. New results from the PANKU-Breast01 trial presented at #ESMO26 found that people taking izalontamab brengitecan (iza-bren), an antibody-drug conjugate, had a median progression-free survival of 8 months, compared to 4 months for those receiving chemotherapy. 🔗 Read more:bit.ly/4ewhPCh #BreastCancer #BreastCancerResearch #ESMO26 #InsightsbyESMO #ClinicalTrials #BreastCancerTreatment #BreastCancerAwareness #Metatvivor

New lidERA trial findings presented at #ESMO26 suggest giredestrant may be easier to tolerate than tamoxifen or aromatase inhibitors for early-stage HR+ breast cancer. Fewer people stopped treatment due to side effects (5% vs. 8%). 🔗 Read more:bit.ly/4ewhPCh #BreastCancer #BreastCancerResearch #BreastCancerAwareness #BreastCancerTreatment

New breast cancer research is in the spotlight at ESMO 2026, with updates on treatments for early-stage and metastatic disease. Explore this weekend’s highlights and what the findings could mean for breast cancer care. bit.ly/4ewhPCh #ESMO2026 #ESMO26 #breastcancer #breastcancerresearch

From early menopause and changes in intimacy to mental health and long-term well-being, there's a lot to navigate after a breast cancer diagnosis — and not all of it gets discussed during oncology appointments. In this episode of The Breastcancer.org Podcast, medical oncologist and Professional Advisory Board member, Dr. Eleonora Teplinsky joins us to discuss her new book, Beyond the Pink: Navigating Life, Health, and Breast Cancer, and the conversations she wishes more people were having about life during and after treatment. 🎧 Watch the full episode or listen wherever you get your podcasts: bit.ly/4rKCSXL #BreastCancer #podcastt #breastcancerwarriors #BreastCancerTreatment #Menopause

Excited to come to @VUMCDiscoveries for the #AYACSM symposium. I'll be speaking about #FinancialToxicity & the unique concerns that #AYAC patients have related to affordability, work, & insurance. Can't wait to join to group of passionate researchers, advocates, & survivors. 🙌

Dr. Nancy Lin (@nlinmd) at the #ESMO26 poster sessions sharing info on the new #BREnna study opening soon @DanaFarber! This phase II/III randomized study focuses on of ZN-A-1041 or tucatinib, in combination with trastuzumab + capecitabine, in patients with HER2+ locally advanced or #MetastaticBreastCancer (HER2+ LA/mBC) with or without central nervous system (#CNS) metastases.

Whether it's the size, shape, symmetry, or how your breasts feel, there may be ways to address some of your concerns. Learn more about possible corrective procedures and adjustment options after surgery to discuss with your surgeon if you are unhappy with your breast reconstruction results. 🔗 bit.ly/3REoVKA #braday #breastreconstructionsurgery #breastcancertreatment #breastcancersurgery

No one should have to live with complications or be dissatisfied with the results of their breast reconstruction surgery. Learn more about corrective breast reconstruction options. 🔗 bit.ly/3TOM2m5 #braday #breastreconstruction #breastcancer #breastcancersurgery

Breast reconstruction with implants can happen in stages, with tissue expanders sometimes used as part of the process. These temporary devices gradually stretch the skin and tissue to make room for a permanent breast implant. 🔗 Learn more about how tissue expanders work and what to expect during breast reconstruction: bit.ly/44vgG9B #braday #breastcancersurgery #implants #breastreconstruction #breastcancer